What is the role of midodrine in patients with decompensated cirrhosis?

Gastroenterology and Hepatology

Volumn 7, Issue 2, 2011, Pages 134-136

  Werling, Klara ^a   Chalasani, Naga ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; FUROSEMIDE; MIDODRINE; OCTREOTIDE;

ASCITES; DECOMPENSATED LIVER CIRRHOSIS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; HEPATORENAL SYNDROME; HUMAN; HYPOTENSION; KIDNEY DISEASE; MEAN ARTERIAL PRESSURE; NOTE; PARACENTESIS; PARACENTESIS INDUCED CIRCULATORY DYSFUNCTION; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 79952804297     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Kashani A, Landavere C, Medici V, Rossaro L. Fluid retention in cirrhosis: pathophysiology and management. QJM. 2008;101:71-85. (Pubitemid 351234707)
2. Gines P, Quintero E, Arroyo V, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122-128. (Pubitemid 17019862)
3. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology. 2006;43:385-394.
4. Tandon P, Tsuyuki RT, Mitchell L, et al. The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int. 2009;29:169-174.
5. Kalambokis G, Fotopoulos A, Economou M, Pappas K, Tsianos EV. Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites. J Hepatol. 2007;46:213-221. (Pubitemid 44959158)
6. Singh V, Dheerendra PC, Singh B, et al. Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study. Am J Gastroenterol. 2008;103:1399-1405. (Pubitemid 351813906)
7. Karwa R, Woodis B. Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications. Ann Pharmacother. 2009;43:692-699.
8. Sourianarayanane A, Barnes DS, McCullough AJ. Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites. Gastroenterol Hepatol (N Y). 2011;7:132-134.
9. Angeli P, Volpin R, Piovan D, et al. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites. Hepatology. 1998;28:937-943. (Pubitemid 28450253)
10. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29: 1690-1697. (Pubitemid 29247040)
11. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40:55-64. (Pubitemid 38868923)
12. Appenrodt B, Wolf A, Grunhage F, et al. Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008;28:1019-1025.
13. Misra VL, Vuppalanchi R, Jones D, et al. The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites. Aliment Pharmacol Ther. 2010;32:1044-1050.
14. Rice JP, Skagen C, Said A. Octreotide, midodrine, and albumin triple therapy does not influence post-liver transplant renal outcomes in patients with hepatorenal syndrome. Hepatology. 2010;52(suppl):A1118.